ISOTAMINE SYRUP

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ISONIAZID

제공처:

BAUSCH HEALTH, CANADA INC.

ATC 코드:

J04AC01

INN (국제 이름):

ISONIAZID

복용량:

10MG

약제 형태:

SYRUP

구성:

ISONIAZID 10MG

관리 경로:

ORAL

패키지 단위:

500ML

처방전 유형:

Prescription

치료 영역:

ANTITUBERCULOSIS AGENTS

제품 요약:

Active ingredient group (AIG) number: 0107349003; AHFS:

승인 상태:

APPROVED

승인 날짜:

2020-12-07

제품 특성 요약

PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
PR
ISOTAMINE
®
Isoniazid, USP
100 mg and 300 mg Tablets
10 mg/mL Syrup
Powder
ANTITUBERCULOSIS AGENT
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
December 7, 2020
Laval, Quebec
H7L 4A8
Control No.: 245927
_Pr_
_ISOTAMINE _
_®_
_ Prescribing Information Page 2 of 19_
PRESCRIBING INFORMATION
PR
ISOTAMINE
®
Isoniazid, USP
100 mg and 300 mg Tablets
10 mg/mL Syrup
Powder
ACTION
Isoniazid may be bacteriostatic or bactericidal in action, depending
on the concentration of the
drug attained at the site of infection and the susceptibility of the
infecting organism. The exact
mechanism of action of isoniazid has not been fully elucidated, but
several mechanisms
including interference with metabolism of bacterial proteins, nucleic
acids, carbohydrates, and
lipids have been proposed. One of the principal actions of the drug
appears to be inhibition of
mycolic acid synthesis in susceptible bacteria which results in loss
of acid-fastness and disruption
of the bacterial cell wall. Isoniazid is active against susceptible
bacteria only when they are
undergoing cell division. Susceptible bacteria may undergo 1 or 2
divisions before multiplication
is arrested.
SPECTRUM
Isoniazid is a highly specific agent and is active only against
organisms of the genus
Mycobacterium. Isoniazid is active _in vitro_ and _in vivo_ against M.
tuberculosis, M. bovis, and
some strains of M. kansasii. _In vitro_, the minimum inhibitory
concentration (MIC) for most
susceptible mycobacteria is 0.02-0.2 mcg/mL in Lowenstein-Jensen
media.
CLINICAL PHARMACOLOGY
ABSORPTION
Isoniazid is readily absorbed from the GI tract. When given with food,
the extent of absorption
and peak plasma concentrations of the drug may be reduced. Following
oral application of the
drug, peak plasma concentrations are attained within 1-2 hours. Plasma
concentrations of the
drug in rapid isoniazid inactivators are 20-50 % of those in slow
isoniazid inactivators.
DISTRIBUTION
Isoniazid is dist